Quoin pharmaceuticals doses first patient in open label netherton syndrome clinical trial

Ashburn, va., march 21, 2023 (globe newswire) -- quoin pharmaceuticals ltd. (nasdaq: qnrx) (the “company” or “quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today announces the dosing of the first patient in its open label clinical trial in netherton syndrome patients.
QNRX Ratings Summary
QNRX Quant Ranking